CLINICAL_TRIALS
trial_result
· 2011-04-27
Clinical Trial Update: Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation. [Phase 3]
Summary
Open-label Phase 3 study evaluating the safety and immunogenicity of a liquid formulation of omalizumab in asthma has completed with results posted in 2011.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2011-04-27